Clik here to view.
Madrigal 'encouraged' by early launch progress of landmark NASH drug
Madrigal Pharmaceuticals is “making great progress” on the rollout of its NASH drug Rezdiffra, executives said less than a month post-launch. Rezdiffra was approved in March as the first treatment for...
View ArticleWhite House unveils long-awaited policy on overseeing research of concern
The White House Office of Science and Technology Policy on Tuesday released its long-awaited policy plans for overseeing research that poses risks if misapplied. The initial reviews from experts are...
View ArticlePatient dies in Pfizer’s Phase 2 Duchenne muscular dystrophy trial
A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the pharma company confirmed. The patient received fordadistrogene movaparvovec in...
View ArticleOscar is winding down its small employer health plans with Cigna
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Oscar Health said Tuesday it plans to stop selling health coverage to small businesses in partnership...
View ArticleAstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future...
AstraZeneca is withdrawing its Oxford-collaborated Covid-19 vaccine from global markets, the UK-based pharma company confirmed in a statement to Endpoints News on Tuesday. The spokesperson said...
View ArticleTeva’s antipsychotic asset passes Phase 3 test in schizophrenia
Teva said Wednesday morning that its schizophrenia drug succeeded in a Phase 3 trial with signs of a differentiated safety profile versus standard of care. The Phase 3 SOLARIS trial set TEV-‘749 — a...
View ArticleClik here to view.
Employers are pulling back from providing mental health benefits, Talkspace...
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Talkspace CEO Jon Cohen told investors during an earnings call Tuesday that some employers have decided...
View ArticleClik here to view.
After CRISPR baby scandal shut down work for years, China gene editing...
A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers are once again performing human studies of...
View ArticleClik here to view.
Isomorphic, Google DeepMind publish latest AI model AlphaFold 3
Google DeepMind and Isomorphic Labs unveiled the newest version of AlphaFold, taking its flagship AI model far beyond predicting the structure of a single protein. AlphaFold 3 can now predict a range...
View ArticleMarinus lays off 20% of workforce, cuts costs to stay afloat
Marinus Pharmaceuticals is cutting about 20% of its workforce and making other cost-cutting changes to extend its cash runway into the first quarter of 2025. The company said Wednesday that it had...
View ArticlePharming ends deal with Orchard; Seres considers cost-cutting
Plus, news about Think Bioscience and Apellis: Pharming axes Orchard pact: The Dutch biopharma terminated a research collaboration and licensing agreement with Orchard Therapeutics due to “current...
View ArticleBeiGene earmarks $74M to build fourth facility in China
BeiGene is building a fourth facility in China with a budget of $74 million for the land and construction. According to its first-quarter earnings in an SEC filing on Wednesday, BeiGene acquired a...
View ArticleTeva to close additional manufacturing sites as it enters next phase of...
Teva is getting ready to close the first chapter of its “pivot to growth” strategy. The company’s restructuring has involved manufacturing site closures, a shift away from some lower-margin generics,...
View ArticleClik here to view.
Inside CVS Caremark’s move that broke Humira’s hold on the market
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until...
View ArticleAfter eight years with Sanofi, Frank Nestle departs as CSO, global head of...
Sanofi’s CSO and global head of research Frank Nestle is leaving the company, a representative confirmed to Endpoints News Wednesday. Nestle first took over both positions in 2020, promoted from his...
View ArticleHouse panel marks up bill to require PBMs to use a flat fee in Medicare
The House Ways and Means committee on Wednesday marked up legislation that would require pharmacy benefit managers to de-link their compensation from the price of a drug, adding to the bipartisan...
View ArticleLawmakers consider limiting how long existing WuXi contracts can continue
House members want drugmakers to end their existing contracts with WuXi AppTec and other Chinese firms by 2032, two sources told Endpoints News. The Biosecure Act, under its current Senate iteration,...
View ArticleCommit Biologics nabs Novo Holdings support in €16M seed round for complement...
Novo Holdings is pitching in to Commit Biologics’ seed funding for its research on “supercharging” antibodies to turn on the complement system, an approach that could potentially lead to treatments for...
View ArticleAardvark raises $85M to target hunger, not appetite, as it contemplates IPO,...
A small San Diego biotech wants to take a different approach to the weight loss drug R&D field by going after hunger rather than suppressing appetite like the wildly popular GLP-1 class. “Most...
View ArticleClik here to view.
Novo Nordisk sees more to GLP-1's future in $600M pact with Flagship's Metaphore
Novo Nordisk is pairing up with another Flagship-founded biotech to create new obesity medications, and GLP-1 remains in the frame. The Danish pharma giant, which leads the GLP-1 field alongside Eli...
View Article